BioSpace News Archive

Drug Development

Merck’s Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial

Merck’s Keytruda has done it again.

January 16, 2018
·
2 min read
·
Mark Terry
Deals

GlaxoSmithKline Rumored to be Mulling $1.65B Bid for Partner Vectura

Speculation around a possible bid has mounted in recent months.

January 16, 2018
·
2 min read
·
Mark Terry
Policy

Starkey Hearing’s Former Execs on Trial for Embezzlement, Fraud

Starkey’s longtime former president Jerry Ruzicka, CFO Scott Nelson and vice president of human resources Larry Miller were all fired in September 2015.

January 16, 2018
·
1 min read
Suzhou Zelgen Biosciences Completes $62M B Round

Suzhou Zelgen Biosciences completed a $62M series B financing to support its portfolio of small molecule and biologic drug candidates.

January 16, 2018
·
1 min read
Job Trends

Regeneron Keeps Science at the Center

Thirty years ago, neurologist Leonard S. Schliefer, MD, PhD, founded Regeneron, a life sciences company dedicated to discovering, developing and bringing new medications to the patients who need them.

January 16, 2018
·
3 min read
·
Jennifer Fink
Job Trends

Look Out: A New Biotech Hub is Emerging in the Bay Area

The new space for biotechs is available following investments from Alexandria Real Estate Equities in this city.

January 16, 2018
·
2 min read
·
Alex Keown
Drug Development

Stock Tanks as Bay Area Eiger Discontinues PAD Drug After Phase II Trial Flop

Shares of Eiger have plunged more than 47 percent this morning after the company announced it is terminating its experimental PAH treatment ubenimex after it flopped its mid-stage study.

January 16, 2018
·
2 min read
·
Alex Keown
Policy

6-Year Old Hallucinates, Tried to Jump Out Window After Taking Roche’s Tamiflu

According to news reports, a six-year-old girl in North Texas was provided Tamiflu and had a rare reaction that affected her nervous system.

January 16, 2018
·
2 min read
·
Alex Keown
Biotech Bay

How 2017 Was Intuitive Surgical’s Year

2017 was a banner year for the leader in robotic surgery. Look and see why investors couldn’t have asked for much more.

January 16, 2018
·
1 min read
BioMidwest

Why This Mostly-Unheard of Colorado Biotech Could Hit $1B in Revenue by 2025

Leah Rush Cann, an analyst with Oppenheimer, launched coverage of this biotech citing the possibility it could exceed $1.2B in revenue by 2025.

January 16, 2018
·
2 min read
·
Mark Terry